知镜 Cognispect · 医学文献与研究工作台

A blood-based metabolic signature for earlier detection of lung cancer.

Irajizad E, Rudsari HK, Gendarme S, Vykoukal J, Wu R, Dennison JB, Karimi N, Darbaniyan F, Moghaddam SJ, Do KA, Feng Z, Ostrin E, Hanash S, Fahrmann JF.
Cell reports. Medicine · 2026-09-23 · PMID 42777710

文献摘要

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to identify metabolic signatures for the earlier detection of lung cancer. We develop a panel of five lung cancer-associated metabolites (L5MetP: diacetylspermine, creatine riboside, arginine, hypoxanthine, and acylcarnitine C18:1) to assess 1-year risk of lung cancer. In the testing set, the L5MetP achieves an area under the receiver operating characteristic curve (AUC) of 0.79 (95% CI: 0.76-0.82) for 1-year risk of lung cancer. The L5MetP also complements existing clinical risk models that predict risk incident lung cancer as well as those that predict death from lung cancer. The L5MetP provides a means for identifying ever-smoker individuals who are lung cancer to inform on the need for lung cancer screening.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。